OVERVIEW
Our annual US-India BioPharma & Healthcare Summit has created an ecosystem bringing together all stakeholders: healthcare and life sciences executives, investors, policy makers and academia. 2009 Summit attracted over 300 senior executives. Our annual Summit has become THE BioPharma event in the world to learn and share for senior executives focused on Drug Discovery & Development, Licensing, Clinical Research, External Research, Healthcare, Innovation, M&A, Deal Flow and Emerging Markets. Senior policy makers from India are regular participants.

The Summit helps facilitate cross border investments, create public-private-academic partnerships and open new opportunities to take the US-India BioPharma and Healthcare business to the next level.

Post summit follow up meetings are held in the US and India. This provides continuity and helps get the results.

    Registration is full. Thank you for your overwhelming support.

Media Partners

HIGHLIGHTS

• Annual high profile summit of established and emerging Biotech, Pharmaceuticals, Medical Devices, Healthcare companies from the US and India, Venture Capitalists, Investment Bankers, Policy Makers and Academia
• Annual R&D spend of just the Advisory Board members in excess of $25 billion
• Annual summit provides continuity and results by bringing all stakeholders together
• Post summit follow up meetings keep the momentum on
• THE Bio Pharma event in the world focused on US-India BioPharma, Medical Devices and Healthcare
• Hear about critical trends directly from the global industry thought leaders and policy makers so you can create successful R&D and emerging market strategies
• Learn about new models in R&D, partnering and commercial models - DIRECTLY from major players who are actually implementing them
• Get face-to-face access to the top global industry thought leaders, investors, academicians and policy makers at one location
• An ideal opportunity to enhance corporate visibility to people who matter
• Large participation by CEOs, Chief Scientific Officers and Chief Medical Officers of Bio, Pharma, Medical Devices and Healthcare companies
• An ideal platform to learn & share. A forum open only to senior executives

Lunch, Cocktails & High Power Networking Reception

View Event Brochure

    Registration is full. Thank you for your overwhelming support.

10-30 AM - 11-00 AM	Registration
11 AM - 11-05 AM	Welcome address by Karun Rishi, President, USA-India Chamber of Commerce
11-05 AM - 11-10 AM	Co-Chair's opening comments- Dr. Martin Mackay, President PharmaTherapeutics R&D, Pfizer
11-10 AM -11-35 AM	Release of annual Position Paper Presentation of USA-India Chamber of Commerce commissioned annual Position Paper by Ajay Dhankar and Vikas Bhadoria, McKinsey & Company
11-35 AM - 12-30 PM	Panel Discussion: Industry-Academia Partnerships: Is there a better prescription to create value? Panelists     Dr. Allen M Spiegel, Dean, Albert Einstein College of Medicine, Yeshiva University     Balu Balasubramanian, PhD, Managing Director, BMS-Biocon R&D Center     Dr. David Golan, Dean of Graduate Education, Harvard Medical School     Dr. Nirmal Ganguly, Chairman JIPMER, Ex-Director General ICMR     Kiran Majumdar-Shaw, Chairman & Managing Director, Biocon Moderator     Dr. Barry R. Bloom Distinguished Service Professor, Harvard School of Public Health
12-30 PM- - 2-00 PM	Panel Discussion - "Show me the Money": Funding innovation, investment opportunities and cross border M&A trends in US-India BioPharma & Healthcare Panelists     Joel Marcus, Chariman and CEO, Alexandria     K.V. Subramaniam, President & CEO, Reliance Life Sciences     Dr. Ansbert Gadicke, Founder & Managing Director, MPM Capital    Utkarsh Palnitkar, Executive Director, Centrum Capital Limited    Brian Atwood, Founding Partner, Versant Ventures Moderator     Jeff Elton, Founder & CEO, KEW Group
2-00 PM - 2-30 PM	Networking & Tea Break
2-30 PM- 2-50 PM	Presentation by Dr. Marc Cluzel, Executive Vice President & Global Head of R&D, Sanofi aventis
2-50 PM - 3-10 PM	Presentation by Dr. Mervyn Turner, Chief Strategy Officer & Senior Vice President Emerging Markets R&D, Merck & Co.
3-10 PM - 4-05 PM	Panel Discussion: Increasing the odds of success - Collaborative Research and Drug Discovery Panelists     Dr. David Lacey, Senior Vice President- Research, Amgen     Dr. Peter Mueller, Executive Vice President, Global R&D & CSO, Vertex Pharmaceuticals    Sri Mosur, Chief Executive Officer, Jubilant Biosys     Dr. Paul Stoffels, Global Head- R&D Pharma, Johnson & Johnson     Davinder Brar, Chairman, GVK Biosciences Moderator     Dr. Martin Mackay, President PharmaTherapeutics R&D, Pfizer
4-05 PM - 4-30 PM	Networking & Tea Break
4-30 PM - 4-50 PM	Presentation by Dr. Rod MacKenzie, Senior Vice President & Head of Worldwide Research, PharmaTherapeutics, Pfizer
4-50 PM - 5-45 PM	Panel Discussion: Moving the needle on Drug Development, Clinical Research & other Healthcare opportunities Panelists     Dr. Michael Rosenblatt, Executive Vice President & Chief Medical Officer, Merck & Co.    Dr. Sanjay Mittal, Director- Clinical Cardiology & Research, Medanta, The Medicity     Dr. Nirmal Ganguly, Chairman JIPMER, Ex-Director General ICMR     Dr. Paul Stoffels, Global Head- R&D Pharma, Johnson & Johnson    Dr. Robert TaberVice Chancellor- Corporate & Venture Devp, Duke University Medical Moderator    Alka Goel, Associate Principal, McKinsey & Company
5-45 PM - 5-50 PM	Closing Remarks - Dr. Gunther Winkler, Sr. Vice President, Biogen Idec
5-50 PM - 7-30 PM	Cocktails & Networking Reception at the Charles View Ballroom, 16th Floor

* Speakers and Timings subject to change                     Please keep your cell phones in the silent mode

Panel Discussions

1. Industry-Academia Partnerships: Is there a better prescription to create value?
   Overall objective: With increasing models of cross-border industry-academia collaborations, this panel will highlight opportunities for Indian and US industry to work with Indian and US academia to accelerate drug discovery and innovation.
   
   Key issues to highlight
   
   1. How to leverage the knowledge, assets and best practices of different stakeholders (US and Indian industry; US and Indian academia)?
   2. What have been some experiences and models that have already shown success?
   3. What additional training or capacity building is required in the areas of Drug discovery, Development and Healthcare where future partnerships could be valuable?
   4. What are potential roadblocks including IP sharing issues , patent pooling (?) for products for developing countries, access to Indian universities?
   5. Are there other countries that do this better than India? We have great universities in India but are they good at cross-border collaboration?
   6. How connected do US Universities feel with Indian healthcare and Indian industry? What would better facilitate that?
   7. How connected do US Biopharma R&D organizations feel with Indian academia? What would better facilitate that?
   8. As part of the Healthcare Reform legislation, the U.S. Government has infused new resources into "comparative effectiveness" research. Are there opportunities for partnership between U.S. academic institutions that have strengths in this area and their Indian counterparts?
   
   
2. "Show me the Money": Funding innovation, investment opportunities and cross border M&A trends in US-India BioPharma & Healthcare.
   Objective: It's not all about the money - but without money there wouldn't be discovery. In the last few years there has been significant PE, VC money by way of funds dedicated to India or more broadly emerging markets. This panel will focus on what investors like about US-India M&A and investment opportunities, and what they wish they could see more of.
   
   Key issues to highlight
   
   1. How is the investor base looking at different opportunities, and what would they would like to see more of?
   2. Which types of transactions and investments have they seen the most value come from?
   3. What are some learnings from the recent crisis and how are they are adapting their investment or acquisition philosophies?
   4. Do they see an opportunity for more large, RBX like deals?
   5. Do they wish that India had a Sovereign Wealth fund? What would that do?
   6. What is the role of government policies to fund innovation and provide seed money?
   7. What are the opportunities for Indian companies to acquire assets of small start-up/innovative companies to take them to the next level due to scarcity of VC funds?
   
   
3. Increasing the odds of success : Collaborative research and drug discovery
   Overall objective: With the rapidly increasing volume and value of US-India deals, this panel will talk about the next level of partnership and collaborative research, ranging from fee for service, performance based to co-development. It will highlight approaches to take these partnerships to the next level.
   
   Key issues to highlight
   
   1. What can we learn from past partnerships?
   2. How have the different panelists forged relationships of trust?
   3. Are there more creative models that could be pursued (e.g. innovative licensing deals, a special investment fund for Indian assets)?
   4. Is there a role that the government can play to be helpful or is this largely a B2B opportunity (e.g. better biotech parks)?
   5. In drug discovery, India/Indian companies have largely played a role in reducing cost. How can they also play a role in reducing attrition more directly?
   6. How can the US Biopharma R&D organizations move towards strategic partnerships with Indian partners rather than principal-vendor relationships?
   
   
4. Moving the needle on Drug Development, Clinical Research and other Healthcare opportunities
   Objective: Drug development represents 50% of the R&D cost base. Over the last decade timelines have increased and costs have sky rocketed. This is also an area where there has already been double digit growth in Indian trial volume. On that platform, this panel will investigate how we can collaborate to deliver drugs on time at lower cost without compromising on quality.
   
   Key issues to highlight
   
   1. What is the incremental opportunity to do more trials in India?
   2. Should pharmacos and CROs develop deeper, direct relationships with megasites and hospitals?
   3. How to better train and cultivate talent (e.g. through industry consortiums)?
   4. How to ensure there is a framework for supporting regulations?
   5. What do pharmacos value the most from Indian trial partners (e.g. project management; TA depth; attention to detail; promptness etc.)?
   6. What are other roadblocks and how to overcome them?
   7. How can the US institutions help the Indian healthcare and delivery system?
   
   

View & Download Event .PDF Brochure

Dr. Martin Mackay President R&D, AstraZeneca	Dr. Paul Stoffels Global Head R&D Pharma Johnson & Johnson	Dr. M.K. Bhan Secretary, Government of India Department of Biotechnology	Ashok Kumar, IAS Secretary, Government of India Department of Pharmaceuticals	Hari S Bhartia Co-Chairman Jubilant Organosys
Dr. Marc Cluzel Executive Vice President & Global Head of R&D Sanofi avantis	Dr. Mervyn Turner Chief Strategy Officer & Senior VP - Emerging Markets Merck & Company	Dr. K.V. Subramaniam Chief Executive Officer Reliance Life Sciences	Prof. Nirmal Kumar Ganguly Padma Bhushan Chairman, JIPMER Pondicherry & Ex Director General ICMR	Dr. Naresh Trehan Chairman Medanta - the Medicity
Dr. Allen M Spiegel Dean, Albert Einstein College of Medicine Yeshiva University	Joel Marcus Chariman and CEO Alexandria	Dr. Barry R. Bloom Professor & Past Dean Harvard School of Public Health	Dr. Peter Mueller Executive Vice President Global R&D & CSO Vertex Pharmaceuticals	Dr. Ansbert Gadicke Founder & Managing Director MPM Capital
D S Brar Chairman GVK Biosciences	Dr. Michael Rosenblatt Executive Vice President & Chief Medical Officer Merck & Company	Dr. David Golan Dean for Graduate Education Harvard Medical School	Dr. Victor Dzau Chancellor for Health Affairs Duke University	Dr. David Lacey Senior Vice President & Head of Research Amgen

View & Download Event .PDF Brochure

REGISTRATION

Participants can register online.
Payment can be made by credit card.
Registration fee: $900.
No walk-ins or at the door registration.

Summit open only to Senior Executives, Enterpreneurs, VCs, Investment Bankers, Private Equity Firms, Academia and Policy makers in the Life Sciences industry (Pharmaceuticals, Biotechnology, Medical Devices and Healthcare).

Restricted entry for Service firms, Sales personnel and Consultants. USA-India Chamber of Commerce reserves the right to decline any registration without assigning any reason

View & Download Event .PDF Brochure

Prithviraj Chavan Minister of State (IC) for Science & Technology and Earth Sciences	Srikant K Jena Minister of State Chemicals & Fertilisers	Dr. M.K.Bhan Secretary, Govt of India Department of Biotechnology	Ashok Kumar, IAS Secretary, Govt of India Department of Pharmaceuticals

View & Download Event .PDF Brochure